NP47827 Multiple Sclerosis Medicines
The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland)
- Value
- £30,403,887
- Published
- 13 Nov 2026
- Deadline
- Not stated
- Procedure
- Not stated
- Category
- 33600000 — Pharmaceutical products
- Location
- UKM
- Notice reference
- 101240-2026
Requirements summary
PSD Scotland, on behalf of NHS Scotland, is planning to establish framework agreements for supply of Multiple Sclerosis medicines, split into three lots: glatiramer acetate, interferon beta-1a and natalizumab; fingolimod, teriflunomide and dimethyl fumarate; and cladribine tablets. The estimated value is GBP 30,403,887 over a maximum 48-month duration, with full goods and volumes to be provided in ITT documents once published.
Key requirements
- Framework agreement for supply of Multiple Sclerosis medicines to NHS Scotland and Integrated Joint Boards
- Lot 1: glatiramer acetate, interferon beta-1a and natalizumab, awarded as unranked multi-supplier framework per product line
- Lot 2: fingolimod, teriflunomide and dimethyl fumarate, awarded as ranked multi-supplier framework per product line
- Lot 3: cladribine tablets, awarded as ranked multi-supplier framework per product line
- Estimated value GBP 30,403,887 covering a maximum 48-month duration including extensions
- Medicine range subject to removal or replacement due to changing litigation landscape; volumes and full goods details to be confirmed in ITT documents